Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) August 1, 2022
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II March 23, 2022
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy December 22, 2021
